MGO One Seven LLC Has $368,000 Stock Position in Enovis Co. (NYSE:ENOV)

MGO One Seven LLC lifted its stake in Enovis Co. (NYSE:ENOV) by 22.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,390 shares of the company’s stock after acquiring an additional 1,538 shares during the period. MGO One Seven LLC’s holdings in Enovis were worth $368,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. lifted its position in Enovis by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company’s stock worth $240,731,000 after purchasing an additional 75,348 shares during the period. DAVENPORT & Co LLC lifted its position in Enovis by 6.0% in the fourth quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company’s stock worth $121,181,000 after purchasing an additional 157,216 shares during the period. Royce & Associates LP lifted its position in Enovis by 2.8% in the fourth quarter. Royce & Associates LP now owns 2,470,576 shares of the company’s stock worth $108,409,000 after purchasing an additional 66,891 shares during the period. River Road Asset Management LLC lifted its position in Enovis by 3.8% in the fourth quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company’s stock worth $54,339,000 after purchasing an additional 45,762 shares during the period. Finally, Boston Partners lifted its position in Enovis by 27.1% in the fourth quarter. Boston Partners now owns 1,048,532 shares of the company’s stock worth $46,034,000 after purchasing an additional 223,816 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Down 1.2 %

Shares of NYSE ENOV opened at $34.67 on Tuesday. The stock has a market cap of $1.98 billion, a PE ratio of -15.83 and a beta of 1.86. The business has a fifty day moving average of $36.51 and a two-hundred day moving average of $42.00. Enovis Co. has a 52-week low of $29.32 and a 52-week high of $56.43. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $560.98 million during the quarter, compared to analysts’ expectations of $555.14 million. As a group, equities research analysts expect that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 target price on shares of Enovis in a research report on Wednesday, April 9th.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.